Serious consequences of COVID-19 were attributed to the immune dysregulation leading to the enhanced production of pro inflammatory mediators (cytokine storm) 3, 4, 5, 6, 7. Hence, adjunctive Pulse D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.ĬOVID-19 pandemic caused by SARS-CoV-2 virus has created an unprecedented hardship in the recent times 1, 2. Therapeutic improvement in vitamin D to 80–100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p < 0.01). Vitamin D level has increased from 16 ± 6 ng/ml to 89 ± 32 ng/ml after Pulse D therapy in VD group and highly significant (p 0.05). Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Differences in the variables between the two groups were analysed for statistical significance. NVD group received standard treatment alone. VD group received Pulse D therapy (targeted daily supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. Subjects were randomised into VD and NVD groups. Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0th day and 9th/11th day as per their respective BMI category. This study aims to objectively investigate the impact of Pulse D therapy in reducing the inflammatory markers of COVID-19. COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator.
0 kommentar(er)
